Zydus Lifesciences rises on getting nod for Bosentan tablets
Zydus Lifesciences is currently trading at Rs. 917.35, up by 7.30 points or 0.80% from its previous closing of Rs. 910.05 on the BSE.
The scrip opened at Rs. 923.65 and has touched a high and low of Rs. 923.65 and Rs. 911.30 respectively. So far 14081 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 923.65 and Rs. 897.50 respectively. The current market cap of the company is Rs. 92015.07 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.85% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Bosentan tablets, oral suspension, 32 mg (USRLD: Tracleer Tablets for Oral Suspension, 32 mg).
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension (PAH), specifically to improve exercise ability and reduce clinical worsening in children (aged 3 years and older) with idiopathic or congenital PAH. It is a dual endothelin receptor antagonist that lowers high blood pressure in the lungs, typically administered based on body weight.
Bosentan 32 mg tablets will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad. Bosentan 32 mg tablets had annual sales of $9.3 million in the United States (IQVIA MAT December 2025). The group now has 432 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04.
